Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
ViGeneron, a Germany-based gene therapy spinout of Ludwig Maximilian University of Munich, on Thursday closed a series A round of undisclosed size co-led by pharmaceutical firm WuXi AppTec and venture capital firm Sequoia Capital China. The money will help progress two platforms targeting ophthalmological conditions: the first, dubbed vgAAV, is a viral vector designed to effectively cross biological barriers within the retina to reach a range of target cells, while a second technique called Revert would restructure larger genes as…
